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Abstract 
Diet-induced obesity and its metabolic consequences can lead to neurological dysfunction and 
increase the risk of developing Alzheimer’s disease (AD) and Parkinson’s disease (PD). Despite 
these realities, the effects of a high fat diet on the central nervous system are not well 
understood. To better understand effects of high fat consumption on the metabolic status of brain 
regions affected by AD and PD, we used magnetic resonance spectroscopy (
1
H-MRS) to measure 
neurochemicals in the hippocampus and in the striatum of rats fed a high-fat diet vs rats fed 
normal low-fat chow. We detected lower levels of total creatine (tCr: phosphocreatine; PCr + 
creatine; Cr) and higher glutamine in both the hippocampus and striatum of high fat-fed rats. 
Additional effects observed in the hippocampus included higher n-acetylaspartylglutamic acid 
(NAAG), and lower myo-inositol (Ins), gamma-Aminobutyric acid (GABA), and serine (Ser). 
Post-mortem tissue analyses revealed lower phosphorylated AMP-activated protein kinase 
(AMPK) and nuclear respiratory factor-1 (NRF-1) protein levels in the striatum but not the 
hippocampus. Overall, these changes indicate diet induced alterations in bioenergetic function 
and neurotransmission within both the hippocampal and striatal tissue.  
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Introduction 
A high fat diet is strongly associated with increased oxidative stress, chronic 
neuroinflammation, altered mitochondrial function, and decreased hippocampal neurogenesis 
and plasticity. Thus, it has been suggested that diet-induced obesity may accelerate age-related 
pathologies and diseases, as well as heighten the brain’s vulnerability to brain insults, which 
contribute significantly to cognitive decline and dementia (Bruce-Keller et al 2009, Uranga et al 
2010). For example, retrospective studies have found that midlife obesity was associated with a 
74% higher chance of developing dementia, while an elevation in BMI of only a single unit was 
associated with a 36% increase in AD. Conversely, those with low fat diets had significantly 
lower risk for AD (Bruce-Keller et al 2009, Whitmer et al 2005). The development of metabolic 
syndrome alone has been demonstrated to increase the risk of AD, while type II diabetes has 
been correlated with AD, increasing an individual’s relative risk by 2-3 fold (Arvanitidis et al 
2009, Leibson et al 1997). In an ex vivo proton nuclear magnetic resonance (
1
H-NMR) study, 6-
hydroxydopamine (6-OHDA)-lesioned rats modeling PD showed altered energy metabolism 
through changes in lactate, alanine, succinate, and Cr in the striatum(Gao et al 2013). These 
defects in energy metabolism have been implicated in various neurodegenerative diseases, and 
are potentially due to defects in mitochondrial ATP production (Sangar et al 2012) and 
alterations in cerebral perfusion and brain microvasculature. These alterations have also been 
shown to occur with obesity (Uranga et al 2010). Overall, there appears to be poorer metabolic 
buffering in CNS-related disorders including diabetes, AD and PD, which could be exacerbated 
by diet-induced obesity. Given the demographic projections of an older and more obese 
population, the public health consequences of these co-morbidities are dire. Despite this reality, 
the effects of a high fat diet on the central nervous system are not well understood. 
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We have conducted several studies examining the effects of a high fat diet on 
nigrostriatal function and vulnerability in young adult rats. We have reported that, like normal 
aging (Cass et al 2002, Marshall et al 1983), a high fat diet increases nigrostriatal dopamine 
(DA) depletion in the 6-OHDA rat model of PD (Morris et al 2010). We have also reported that 
unlesioned rats fed a high fat diet exhibit substantially attenuated striatal DA release and 
increased iron levels and markers of oxidative stress in the substantia nigra (Morris et al 2011). 
These findings also parallel findings reported for normal aging (Drayer et al 1986, Hebert & 
Gerhardt 1998, Ke et al 2005, Venkateshappa et al 2012a, Venkateshappa et al 2012b). Overall, 
these results support the hypothesis that a high fat diet produces significant adverse effects on 
neurological function. It is possible that disrupted brain energy metabolism plays a role in these 
effects. 
Deriving primarily from glucose metabolism, the brain’s high energy consumption makes 
it vulnerable to impaired energy production. Defects in glucose homeostasis, including hypo- and 
hyper-glycemia, adversely affect human brain health and cognitive function (Biessels et al 2006, 
Craft 2005). Diet-induced obesity can result in reduced cerebral glucose utilization, even where 
the majority of glucose utilization has not been shown to rely on insulin (Levin 1991). Insulin 
resistance, glucose transport abnormalities, and altered cerebral glucose metabolism are 
pathophysiological features associated with mitochondrial dysfunction that have been 
demonstrated to occur with AD. These events can appear up to decades prior to cognitive decline 
and pathological alterations (Businaro et al 2012, Chen & Zhong 2013), linking obesity with an 
increased  risk of developing AD.  
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To better understand the effects of high fat consumption on the metabolic status of brain 
regions affected by AD and PD, we used magnetic resonance spectroscopy (
1
H-MRS) to measure 
neurochemicals in the hippocampus and striatum of rats fed a high-fat diet vs rats fed normal 
low-fat chow. 
1
H-MRS is a powerful and non-invasive brain imaging technique that our group 
has used to measure the effects of normal aging and traumatic brain injury on brain metabolic 
signatures (Harris et al 2012, Harris et al 2014). This technique is able to quantify up to 20 
neurochemicals in a given region of interest (ROI). The goal of the current study was to generate 
similar metabolic signatures for the neural effects of a high fat diet. We also measured proteins 
related to bioenergetic function in hippocampal and striatal tissue collected post mortem. 
Materials & Methods 
Animals and diet.  
Two month old male F344 rats were given access ad libitum to a high fat diet (60% 
calories from fat, n=6) or standard rat chow (4% calories from fat, n=6) for five months. This 
high fat feeding protocol is an established model of insulin resistance characterized by increased 
adiposity and hyperglycemia.  Body weights were 374 ± 9 g and 420 ± 8 g for the chow and high 
fat groups respectively (p<0.001) on the day of imaging (Table 1).  
Magnetic Resonance Imaging and Spectroscopy  
Animals were fasted for 12 hours prior to the imaging procedure. Isoflurane was 
administered for 4 minutes at 4% prior to placing the animal in the magnet cradle where 
anesthesia was maintained at 1.5-3% during imaging. During imaging, respiration was monitored 
and body temperature was maintained at 37°C via a feedback control system. We collected 
water-suppressed STEAM spectra (Varian 9.4T spectrometer, TE=2ms, TR=4000ms) from two 
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ROI over the hippocampus and striatum (Figure 1). First and second order shims were adjusted 
using FASTMAP, and spectra (Figure 2) were analyzed with LCModel as described previously 
(Harris et al 2014).  
Western Blot 
Antibodies against NRF1, TFAM, phosph-AMPK, and total AMPK were obtained from 
Cell Signaling Technology (Beverly, MA), and antibodies against PGC1α were obtained from 
Calbiochem (San Diego, CA ). Antibodies against Actin were obtained from Abcam 
(Cambridge, MA). Goat-anti-rabbit HRP-conjugated secondary antibodies were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA). Enhanced chemiluminescence reagents were 
purchased from Thermo Scientific (Waltham, MA). All other reagents were obtained from Sigma 
(St.Louis, MO). 
Brains were extracted after MRS procedures were complete and tissue was dissected 
using a stainless steel adult rat brain slicer matrix with 1.0 mm coronal slice intervals. Sections 
of the hippocampus and striatum were dissected from the slices and frozen for later analysis.   
Samples were processed for protein analysis as described previously (Morris et al 2008). 
Frozen samples were diluted in cell extraction buffer and the tissue was homogenized and 
centrifuged. A Bradford assay was performed in triplicate to determine sample protein 
concentrations and then diluted to obtain samples of constant concentration for analysis with 
SDS-PAGE. All samples were run on 10% gels and then transferred to nitrocellulose 
membranes, followed by blocking and incubation with primary and secondary antibodies for 
proper time intervals. Upon exposure, films were scanned at high resolution to obtain digital 
images. Densitometry analyses were performed using Image J software. 
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Statistical Analysis  
For the MRS measurements, only those with Cramer-Rao lower bounds ≤ 30 were 
accepted. Neurochemical levels in the HF vs. control groups were compared using a weighted 
averages method, and corrected for multiple comparisons, as previously described (Harris et al 
2014).  
Protein concentrations obtained with western immunoblot were compared between 
groups using an unpaired Student’s t-test. Data are shown as the mean and standard error. For all 
analyses, statistical significance was set at p<0.05. 
Results 
Neurochemical changes induced by a high fat diet in fasted animals.  
Using 
1
H-MRS, we evaluated 20 neurochemicals in two brain regions after 5 months of a 
high fat or standard chow diet (Table 2). These data showed that a long term high fat diet induces 
neurochemical changes in the striatum and hippocampus. Decreases in striatal (p=0.007) and 
hippocampal (p=0.007) tCr and increases in striatal (p=0.048) and hippocampal (p=0.010)gln 
were significant. The hippocampus showed changes in GABA (p=0.046), NAAG (p=0.003), Ins 
(p=0.003), and Ser (p=0.001) levels with the high fat diet as well. These neurochemicals were 
not affected in the striatum.  
Protein effects of long term high fat diet.  
We measured levels of three mitochondrial proteins and activation of AMPK in the 
striatum and hippocampus of fasted animals using western immunoblot (Figure A1). There was 
evidence of lower AMPK phosphorylation and NRF1 expression in the striatum of the high fat 
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fed animals (Fig. 3a, p=0.047, 0.025), while there were no significant diet effects in the 
hippocampus (Fig. 3b).  While the effect did not reach statistical significance, PGC1α levels 
were lower in the striatal tissue (Fig. 3a, p=0.065) further suggesting mitochondrial alterations 
induced by the high fat diet.  
Correlation between tCr and AMPK activation.  
 In order to determine relationships between imaging and tissue findings, we conducted 
correlation analyses (Table A1 of Appendix A). These analyses revealed a strong positive 
correlation between tCr levels and AMPK activation (r =0.708; p=0.000) Animals with lower tCr 
also had lower pAMPK/AMPK (Figure 4). This effect was strongest in the hippocampus 
(r=0.738; p=0.009; Figure 5).  
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Table 1 – Weight changes in control and high fat fed groups.  
  
Starting Weight 
(g) 
Ending Weight 
(g) Weight Gain (g) %Weight Gain 
Control 265 ± 3 374 ± 9 109 ± 10 41.1 
High Fat 266 ± 4 420 ± 8 154 ± 9 57.9 
p value 0.44 0.0009 0.0007   
Values are group means with standard error. p < 0.05 is denoted in bold.  
 
Figure 1 - Sample voxels chosen for H-MRS. Regions of interest for hippocampus (left) and 
striatum (right) as identified on anatomical MRI taken from the coronal (top) and sagittal 
(bottom) planes.  
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Figure 2 - Sample H-MRS Spectra 
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Table 2 – Neurochemical changes in the high fat fed vs. control animals.  
 
Hippocampus     
 
Striatum     
 Control High Fat p  Control High Fat P 
Ala 0.39 ± 0.04 0.38 ± 0.04 0.804 
 
0.58 ± 0.05 0.45 ± 0.07 0.159 
Asc 2.84 ± 0.26 2.33 ± 0.09 0.078 
 
2.28 ± 0.16 2.13 ± 0.10 0.423 
Asp 1.54 ± 0.23 1.31 ± 0.16 0.415 
 
0.81 ± 0.15 0.83 ± 0.14 0.929 
Cr 3.79 ± 0.11 3.28 ± 0.18 0.050 
 
3.72 ± 0.21 3.42 ± 0.20 0.319 
PCr 5.95 ± 0.24 5.58 ± 0.15 0.221 
 
5.48 ± 0.28 5.34 ± 0.17 0.686 
tCr 9.70 ± 0.22 8.77 ± 0.17 0.007 
 
9.28 ± 0.17 8.80 ± 0.12 0.038 
GABA 1.38 ± 0.06 1.20 ± 0.05 0.046 
 
 1.43 ± 0.10 1.33 ± 0.05 0.393 
Glc 3.75 ± 0.57 3.34 ± 0.22 0.497 
 
4.34 ± 0.49 5.09 ± 0.18 0.177 
Gln 3.29 ± 0.12 3.71 ± 0.13 0.048 
 
4.14 ± 0.12 4.62 ± 0.10 0.010 
Glu 10.12 ± 0.05 9.59 ± 0.21 0.055 
 
9.02 ± 0.15 9.06 ± 0.11 0.821 
GPC 0.94 ± 0.07 0.81 ± 0.07 0.216 
 
0.90 ± 0.04 0.81 ± 0.09 0.396 
PCho 0.24 ± 0.04 0.22 ± 0.03 0.797 
 
0.57 ± 0.04 0.55 ± 0.05 0.746 
tCho 1.19 ± 0.08 1.04 ± 0.07 0.169 
 
1.46 ± 0.03  1.37 ± 0.07 0.300 
GSH 0.90 ± 0.07 0.85 ± 0.05 0.604 
 
0.99 ± 0.03 0.98 ± 0.02 0.801 
Ins 8.39 ± 0.21 7.35 ± 0.16 0.003 
 
6.770 ± 0.13 6.49 ± 0.14 0.187 
Lac 1.53 ± 0.07 1.63 ± 0.12 0.499 
 
2.42 ± 0.35 1.78 ± 0.13 0.111 
NAA 9.75 ± 0.11 9.72 ± 0.15 0.884 
 
8.09 ± 0.26 8.36 ± 0.13 0.377 
NAAG 0.82 ± 0.04 1.04 ± 0.04 0.003 
 
0.98 ± 0.11 0.93 ± 0.04 0.656 
PE 1.54 ± 0.41 1.58 ± 0.05 0.928 
 
1.93 ± 0.19 1.85 ± 0.17 0.785 
Ser 1.73 ± 0.18 0.82 ± 0.08 0.001 
 
1.92 ± 0.22 1.73 ± 0.29 0.614 
Tau 6.58 ± 0.19 6.38 ± 0.12 0.382  7.60 ± 0.21 7.52 ± 0.17 0.772 
PCr/Cr 1.58 ± 0.14 1.72 ± 0.15 0.505  1.50 ± 0.14 1.56 ± 0.09 0.734 
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Neurochemical concentrations are expressed as mmol/g wet tissue weight. Values are weighted group 
means and weighted standard error. p < 0.05 is denoted in bold. Key: Ala, alanine; Asc, ascorbate, Asp, 
aspartate; Cr, creatine; GABA, gamma aminobutyric acid; Glc, glucose; Gln, glutamine; Glu, glutamate; 
GPC, glycerophosphocholine; GSH, glutathione; Ins, myo-inositol; Lac, lactate; NAA, N-acetylaspartate; 
NAAG, N-acetylaspartyl glutamate; PCho, phosphocholine; PCr, phosphocreatine; PE, 
phosphoethanolamine; Ser, serine; Tau, taurine; tCho, total choline (GPC & PCho); tCr, total creatine (Cr 
& PCr). 
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Figure 3 - Western immunoblot quantification of proteins in (a) striatal and (b) hippocampal 
tissue. 
3a. Striatum 
  
TFAM, p= 0.774; NRF1, p= 0.025; PGC1α, p= 0.065; pAMPK/AMPK, p= 0.047 
 
3b. Hippocampus  
 
 
TFAM, p= 0.593; NRF1, p= 0.397; PGC1α, p= 0.542; pAMPK/AMPK, p= 0.258   
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Figure 4 - Total Creatine vs. Activation of AMPK in Brains of Fasted Rats 
 
Measurements from control animals are indicated by triangle data points, and high fat fed animals by 
diamond data points. The correlation coefficient, r, is given and indicates a strong correlation between 
levels of total creatine and AMPK activation. This data is also shown for striatum and hippocampus tissue 
samples separately in Figures 5a and 5b.  
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Figure 5 – Total Creatine vs. Activation of AMPK  in Striatum and Hippocampus 
5a. Striatum 
 
 
5b. Hippocampus 
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Discussion 
This study reveals bioenergetic and metabolic neuronal changes induced by a high fat 
diet. While we did not observe evidence of significant oxidative stress or chronic inflammation 
known to be associated with the high fat diet, we did detect changes suggesting disrupted energy 
homeostasis and altered neurotransmission in both the hippocampus and striatum. The results of 
this study can assist in identifying mechanisms for how a high fat diet affects these brain tissues 
early on, and help elucidate the link between a diet high in fat  and the development of 
neurodegenerative disease.  
Decreases in total creatine & AMPK activation 
Creatine (Cr) and phosphocreatine (PCr) are known to play a central role in energy 
metabolism, buffering against rapid changes in ADP/ATP ratios (Choe et al 2013). At times of 
high energy demand, PCr can be used to fuel metabolic needs, resulting in a decreased PCr:Cr 
ratio. Conversely, PCr can be reserved during times of low energy demand, resulting in higher 
PCr:Cr ratios providing an energy supply buffer, and signaling other pathways that are involved 
in energy regulation and homeostasis. While the individual values of Cr and PCr did not differ 
significantly between groups, Cr levels accounted for more of the reduction in tCr than pCr. 
Given this, we should have measured greater PCr:Cr ratios  in the HF-fed animals. However, 
PCr:Cr ratios were similar between groups (Table 2). Alterations in the Cr-PCr system should 
result in diminished capacity to buffer energy needs and to activate further signaling cascades 
involved in metabolic regulation. Because PCr:Cr ratios did not differ between groups, we are 
unsure if the changes in Cr were related to the lower activation of AMPK in the high fat-fed 
animals. We did measure a strong correlation between tCr levels and AMPK activation (Figure 
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4). In general, it appears that the high fat-fed animals have lower tCr and lower AMPK activation 
in both brain regions. The immunoblot data did not show a significant difference in AMPK 
activation in the hippocampus, yet this is where the strongest correlation between Cr and AMPK 
was measured (Figure 5). Together, these data suggest that lower levels of tCr can potentially 
impact downstream events such as the activation of AMPK, even if PCr:Cr ratios are unchanged. 
One study reported that Cr deficiency actually induces chronic Cr-dependent activation of 
AMPK, stimulating catabolic pathways and providing protection against diet induced obesity 
(Choe et al 2013).  
Because Cr levels are generally  assumed to remain relatively constant, they are often 
used as an internal reference. However, under certain physiological conditions, such as 
hyperglycemia, this does not hold true (Karczewska-Kupczewska et al 2013). The lower Cr 
found in our study could potentially be due to reduced levels of Cr precursors or synthesis-
related enzymes such as arginine:glycine amidinotransferase (AGAT). AGAT activity is 
regulated by growth hormone and thyroxine, both of which have been shown to be affected by 
high fat diets, obesity, and diabetes (List et al 2009, Lu et al 2013). Reduced Cr kinase activity 
was shown to be associated with HFD-induced metabolic changes (Amin et al 2011)  and has 
been measured in the brains of streptozotocin- induced diabetic rats (Zhao et al 1999). It is 
possible that this effect is due to increased ROS production under these conditions (Genet et al 
2000). Reduced Cr kinase activity should create a less efficient Cr-PCr system and likely affects 
total Cr levels. 
AMPK is a protein coupled to whole body and cellular energy status, and is a major 
regulator of energy metabolism. AMPK is sensitive to cellular AMP/ATP ratios and becomes 
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activated via AMP binding and phosphorylation at its Thr172 residue by upstream kinases at 
times of metabolic stresses (Amato & Man 2011). Elevated energy demand also decreases the 
PCr:Cr ratio, which also plays a role in Cr-dependent AMPK activity(Choe et al 2013). Neurons 
are the most metabolically demanding cells. Because energy demand is coupled to glucose 
uptake, it has been suggested that AMPK plays a role in the glucose transport system in the brain 
(Amato & Man 2011).  
Here, we found that a high fat diet was associated with lower phosphorylation of AMPK. 
This suggests either lower cellular energy demand, or less than optimal responses to energy 
demand by the cell.  Reduction in AMPK activation is associated with obesity and plays a role in 
neurodegenerative diseases such as AD (Amato & Man 2011). Additionally, studies have shown 
that treatments providing chronic activation of AMPK can protect against diet-induced obesity, 
creating a potential treatment for obesity or T2D (Amato & Man 2011, Kahn et al 2005, 
Sarnowska et al 2013, Sung et al 2014, Woo et al 2014).  Under normal (non-obese) conditions, 
increased leptin would accompany increased fat, followed by an increase in fatty acid oxidation 
via activation of AMPK (Yang & Barouch 2007). Leptin resistance is associated with obesity 
however, which may explain the reduced activation of AMPK that we observed, and may 
portend less oxidation of fatty acids. Overall, animals in the high fat group exhibited signs of 
diminished buffering capacity for energy metabolism, and poorer control of the signaling 
cascades which regulate cellular energy metabolism. 
Increases in glutamine.  
 After glutamate (Glu) release, Gln is rapidly synthesized by glutamine synthase to allow 
for rapid Glu clearance as part of the Glu-Gln cycle. Because of this rapid process, changes in 
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Gln levels likely reflect Glu neurotransmission. The changes in Gln with high fat consumption 
which were seen here could be evidence of low grade chronic excitotoxicity, resulting in 
neuronal damage or cell death within these tissues. Obesity has been shown to impair synaptic 
transmission (Sickmann et al 2010, Valladolid-Acebes et al 2012), potentially due to changes in 
myelination (Bruce-Keller et al 2009). This increase in Gln could be explained by increases in 
glutamine synthase activity or upregulation of other mechanisms involved in Glu clearance 
which have been found in studies of diet-induced obesity  (Langley & York 1990, Valladolid-
Acebes et al 2012). It was suggested that these mechanisms result from excessive glucocorticoid 
activity and desensitized NMDA receptors. Obesity-associated leptin deficiency has also been 
shown to increase hypothalamic cerebral activation, indicating higher neuronal oxidative 
metabolism and Glu neurotransmission (Delgado et al 2011). Various studies have also shown 
obesity to be linked to altered Glu-Gln cycling; however, the direction of obesity-induced 
changes is inconsistent across studies (Langley & York 1990, Sickmann et al 2010, Sookoian & 
Pirola 2012, Valladolid-Acebes et al 2012).  
As mentioned previously, obesity can affect brain glucose metabolism and energy 
homeostasis. Gln could play a role in these processes. As a product of the TCA cycle, we would 
expect increases in Gln if the TCA cycle is not functioning efficiently due to reduced TCA cycle 
enzymatic activity or mitochondrial dysfunction. Reduced brain glucose metabolism has been 
reported in models of obesity and type II diabetes, with a larger reduction in glucose metabolism 
via the TCA cycle than through glycolysis (Sickmann et al 2010). Similar alterations in 
neurotransmission and cerebral energy metabolism have been associated with aging (Harris et al 
2014) and neurodegenerative diseases such as AD (Chen & Zhong 2013, Uranga et al 2010). 
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Decreased NRF1 expression  
NRF1 is a mitochondrial protein responsible for mDNA transcription and replication as 
well as aerobic respiration (Uranga et al 2010). Several studies have reported links between diet-
induced metabolic disturbances and mitochondrial alterations. For example, high fat diets have 
been shown to negatively affect the generation of energy in mitochondria, likely due to decreases 
in complex I activity (Nisoli et al 2007, Uranga et al 2010). Decreased expression of genes 
involved in mitochondrial biogenesis have also been observed (Bruce-Keller et al 2009, Sangar 
et al 2012, Uranga et al 2010). Altered biogenesis and efficiency of the mitochondrial machinery 
would be expected to compromise energy availability in the brain.  
The mitochondrial changes reflected by lower NRF1 expression could also play a role in 
dysfunctional energy metabolism in the striatum, as suggested by the observed changes in tCr 
and pAMPK. Whether these changes occurred concomitantly, or one as the result of the other, 
we believe they reflect early changes in the metabolic machinery in the striatum. Although the 
effect did not reach significance, the lower levels of PGC1α in the striatum of the high fat-fed 
rats provide further evidence for mitochondrial alterations in this tissue.   
Additional changes in hippocampal neurochemicals.  
  While the striatum showed evidence of alterations in protein expression, the hippocampus 
had greater neurochemical changes detected via MRS. Lower levels of Ser, GABA, and Ins 
along with higher levels of NAAG indicate further alterations in brain metabolism in this brain 
region. 
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Ser binds to NMDA receptors acting as a co-agonist and modulator of neurotransmission 
and neurotoxicity at glutamatergic synapses (Mohd Zain et al 2012, Radzishevsky et al 2013, 
Wolosker et al 2008), while GABA functions as the main inhibitory neurotransmitter in the CNS. 
The lower levels of striatal Ser and GABA shown here further suggest obesity-induced 
disruption of neurotransmission and could potentially lead to excitotoxicity. Additionally, we 
saw increases in striatal NAAG, a peptide neurotransmitter which binds to NMDA receptors 
(Bergeron & Coyle 2012, Bergeron et al 2004). It is likely that the increase in NAAG also plays 
a role in altered neurotransmission homeostasis alongside the changes in Gln, Ser and GABA.  
 Ins has been recognized as a glial cell marker, second messenger, osmoregulator and cell 
membrane constituent (Karczewska-Kupczewska et al 2013). Obesity and insulin resistance have 
been linked to early cerebral changes of Ins; however it was higher levels of Ins that were 
observed rather than the lower levels we measured in the hippocampus of our high fat-fed 
animals (Gonzales et al 2012, Haley et al 2010, Haley et al 2013, Karczewska-Kupczewska et al 
2013). Higher levels of Ins are also associated with neurological disorders, including AD 
(Karczewska-Kupczewska et al 2013).  There are also studies, however, that link increased levels 
of intracellular Gln with lower Ins (Shawcross et al 2004).  These findings may indicate a 
buffering system in the context of cellular metabolic disturbances, and our findings may indicate 
a similar mechanism in the hippocampus of high fat-fed rats. 
 
Summary 
Our findings indicate that a long-term high fat diet in adult rats induces significant 
metabolic changes, suggesting bioenergetic dysfunction as well as alterations in 
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neurotransmission. With the presence of obesity and metabolic disorders on the rise, it is 
important to develop an understanding of these early diet-induced changes within the CNS in 
order to determine the link to cognitive decline and increased risk of neurological disorders.  Our 
study provides evidence of changes that can be detected with a non-invasive neuroimaging 
technique that could be translated to human studies, furthering the potential for developing 
therapeutic options for cognitive impairment in individuals with metabolic disorders. 
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Appendix A 
Table A1 – Correlation Matrix of all 
1
H-MRS and Western Immunoblot Data 
  pAMPK/AMPK Cr+PCr Mac Ala Asc Asp bHB GPC 
pAMPK/AMPK 
r 1 .708
**
 0.213 -0.225 0.09 .658
**
 0.149 0.099 
p    0 0.329 0.302 0.683 0.001 0.497 0.653 
Cr+PCr r .708
**
 1 -0.148 -0.19 0.357 .645
**
 0.126 0.388 
  p  0   0.49 0.373 0.087 0.001 0.558 0.061 
Mac r 0.213 -0.148 1 -0.188 0.012 0.225 -0.368 -0.203 
  p  0.329 0.49   0.379 0.957 0.29 0.077 0.342 
Ala r -0.225 -0.19 -0.188 1 -0.262 -.548
**
 0.209 -.446
*
 
  p  0.302 0.373 0.379   0.216 0.006 0.326 0.029 
Asc r 0.09 0.357 0.012 -0.262 1 .476
*
 -0.233 .667
**
 
  p  0.683 0.087 0.957 0.216   0.019 0.274 0 
Asp r .658
**
 .645
**
 0.225 
-
.548
**
 
.476
*
 1 -0.057 0.364 
  p  0.001 0.001 0.29 0.006 0.019   0.79 0.081 
bHB r 0.149 0.126 -0.368 0.209 -0.233 -0.057 1 -0.053 
  p  0.497 0.558 0.077 0.326 0.274 0.79   0.804 
GPC r 0.099 0.388 -0.203 -.446
*
 .667
**
 0.364 -0.053 1 
  p  0.653 0.061 0.342 0.029 0 0.081 0.804   
PCho r -0.365 -0.219 
-
.617
**
 
.565
**
 -0.344 -.635
**
 0.253 -0.219 
  p  0.086 0.304 0.001 0.004 0.1 0.001 0.233 0.304 
Cr r 0.168 .480
*
 -0.266 -0.198 0.365 0.192 -0.156 .527
**
 
  p  0.443 0.018 0.209 0.355 0.079 0.369 0.466 0.008 
PCr r .613
**
 .645
**
 0.074 -0.03 0.062 .519
**
 0.269 -0.047 
  p  0.002 0.001 0.73 0.888 0.773 0.009 0.203 0.828 
GABA r 0.142 0.291 
-
.597
**
 
0.118 0.089 0.042 0.206 0.18 
  p  0.519 0.168 0.002 0.584 0.68 0.847 0.334 0.401 
Glc r -.662
**
 -0.307 
-
.564
**
 
0.355 0.106 -.460
*
 0.103 0.075 
  p  0.001 0.144 0.004 0.088 0.623 0.024 0.633 0.729 
Gln r -.415
*
 -0.266 -0.294 0.303 -.511
*
 -.444
*
 0.15 -0.232 
  p  0.049 0.208 0.163 0.15 0.011 0.03 0.484 0.274 
Glu r .447
*
 .556
**
 0.344 -0.392 .508
*
 .718
**
 -0.159 0.287 
  p  0.032 0.005 0.1 0.058 0.011 0 0.458 0.174 
GSH r -0.268 -0.057 -0.265 0.316 0.221 -0.279 -0.053 .449
*
 
  p  0.216 0.793 0.211 0.133 0.3 0.187 0.806 0.028 
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  pAMPK/AMPK Cr+PCr Mac Ala Asc Asp bHB GPC 
Ins r .559
**
 .703
**
 0.311 -.448
*
 .650
**
 .807
**
 -0.097 .411
*
 
  p  0.006 0 0.14 0.028 0.001 0 0.653 0.046 
Lac r -0.054 -0.188 -0.021 0.358 -.458
*
 -.486
*
 0.342 -0.249 
  p  0.807 0.38 0.922 0.086 0.024 0.016 0.102 0.241 
NAA r .414
*
 0.391 .438
*
 
-
.530
**
 
0.404 .703
**
 -0.331 0.091 
  p  0.049 0.059 0.032 0.008 0.05 0 0.114 0.672 
NAAG r -0.229 -.458
*
 -0.045 0.207 -0.387 -0.382 0.217 -.407
*
 
  p  0.292 0.025 0.833 0.333 0.062 0.066 0.308 0.048 
PE r 0.398 0.169 -0.009 0.212 
-
.721
**
 
0.013 0.333 -.479
*
 
  p  0.06 0.429 0.965 0.32 0 0.953 0.112 0.018 
Ser r -0.334 0.15 
-
.636
**
 
0.021 0.367 -0.163 0.042 .607
**
 
  p  0.119 0.484 0.001 0.924 0.078 0.445 0.846 0.002 
Tau r 0.067 0.221 -.410
*
 0.2 -.407
*
 -0.193 0.253 0.034 
  p  0.76 0.3 0.047 0.348 0.048 0.366 0.233 0.874 
NAA+ NAAG r 0.376 0.297 .437
*
 -.494
*
 0.326 .632
**
 -0.289 0.002 
p  0.077 0.159 0.033 0.014 0.12 0.001 0.17 0.992 
Glu+Gln r 0 0.288 0.033 -0.075 -0.037 0.259 0 0.043 
  p  1 0.173 0.877 0.729 0.864 0.222 1 0.844 
GPC+  PCho 
r -0.255 0.094 
-
.680
**
 
0.162 0.19 -0.282 0.179 .541
**
 
p  0.241 0.661 0 0.45 0.373 0.182 0.401 0.006 
PGC1α r 0.061 -0.108 -0.186 0.301 -0.145 -0.21 0.096 -0.362 
  p  0.782 0.623 0.396 0.162 0.51 0.336 0.662 0.09 
NRF1 r 0.19 -0.042 -0.111 0.372 -0.068 -0.106 0.212 -0.299 
  p  0.386 0.848 0.615 0.08 0.759 0.631 0.332 0.166 
TFAM r .431
*
 0.23 .544
**
 -0.18 0.297 .624
**
 -0.112 -0.033 
  p  0.04 0.29 0.007 0.41 0.169 0.001 0.611 0.881 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
( r )Pearson Correlation  
  ( p)2-Tailed Significance  
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Table A1 (continued) 
  PCho Cr PCr GABA Glc Gln Glu GSH 
pAMPK/AMPK 
r -0.365 0.168 .613
**
 0.142 -.662
**
 -.415
*
 .447
*
 -0.268 
p  0.086 0.443 0.002 0.519 0.001 0.049 0.032 0.216 
Cr+PCr r -0.219 .480
*
 .645
**
 0.291 -0.307 -0.266 .556
**
 -0.057 
  p  0.304 0.018 0.001 0.168 0.144 0.208 0.005 0.793 
Mac r -.617
**
 -0.266 0.074 -.597
**
 -.564
**
 -0.294 0.344 -0.265 
  p  0.001 0.209 0.73 0.002 0.004 0.163 0.1 0.211 
Ala r .565
**
 -0.198 -0.03 0.118 0.355 0.303 -0.392 0.316 
  p  0.004 0.355 0.888 0.584 0.088 0.15 0.058 0.133 
Asc r -0.344 0.365 0.062 0.089 0.106 -.511
*
 .508
*
 0.221 
  p  0.1 0.079 0.773 0.68 0.623 0.011 0.011 0.3 
Asp r -.635
**
 0.192 .519
**
 0.042 -.460
*
 -.444
*
 .718
**
 -0.279 
  p  0.001 0.369 0.009 0.847 0.024 0.03 0 0.187 
bHB r 0.253 -0.156 0.269 0.206 0.103 0.15 -0.159 -0.053 
  p  0.233 0.466 0.203 0.334 0.633 0.484 0.458 0.806 
GPC r -0.219 .527
**
 -0.047 0.18 0.075 -0.232 0.287 .449
*
 
  p  0.304 0.008 0.828 0.401 0.729 0.274 0.174 0.028 
PCho r 1 0.014 -0.245 0.257 .646
**
 .661
**
 -.569
**
 0.339 
  p    0.949 0.249 0.225 0.001 0 0.004 0.105 
Cr r 0.014 1 -0.361 0.394 0.011 -0.111 0.038 0.274 
  p  0.949   0.083 0.057 0.96 0.604 0.859 0.194 
PCr r -0.245 -0.361 1 -0.034 -0.336 -0.186 .557
**
 -0.299 
  p  0.249 0.083   0.874 0.108 0.384 0.005 0.156 
GABA r 0.257 0.394 -0.034 1 0.37 -0.068 -0.021 0.232 
  p  0.225 0.057 0.874   0.075 0.753 0.922 0.275 
Glc r .646
**
 0.011 -0.336 0.37 1 0.384 -0.353 .470
*
 
  p  0.001 0.96 0.108 0.075   0.064 0.091 0.021 
Gln r .661
**
 -0.111 -0.186 -0.068 0.384 1 -.576
**
 0.364 
  p  0 0.604 0.384 0.753 0.064   0.003 0.08 
Glu r -.569
**
 0.038 .557
**
 -0.021 -0.353 -.576
**
 1 -0.202 
  p  0.004 0.859 0.005 0.922 0.091 0.003   0.343 
GSH r 0.339 0.274 -0.299 0.232 .470
*
 0.364 -0.202 1 
  p  0.105 0.194 0.156 0.275 0.021 0.08 0.343   
Ins r -.632
**
 0.289 .496
*
 0.053 -0.335 -.653
**
 .842
**
 -0.254 
  p  0.001 0.171 0.014 0.804 0.109 0.001 0 0.232 
Lac r 0.343 0.15 -0.33 0.056 -0.099 0.34 -.522
**
 0.117 
  p  0.101 0.485 0.116 0.796 0.645 0.104 0.009 0.587 
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  PCho Cr PCr GABA Glc Gln Glu GSH 
NAA r -.742
**
 0.038 0.382 -0.083 -.467
*
 -.619
**
 .841
**
 -0.399 
  p  0 0.859 0.066 0.701 0.021 0.001 0 0.054 
NAAG r 0.08 -0.138 -0.366 0.175 0.133 0.089 -.490
*
 -0.18 
  p  0.709 0.52 0.078 0.413 0.536 0.679 0.015 0.399 
PE r 0.109 -0.15 0.31 0.074 -0.339 0.33 -0.326 -0.232 
  p  0.613 0.484 0.14 0.73 0.105 0.115 0.12 0.276 
Ser r .501
*
 .541
**
 -0.311 0.376 .620
**
 0.227 -0.135 .495
*
 
  p  0.013 0.006 0.139 0.07 0.001 0.287 0.53 0.014 
Tau r .559
**
 0.2 0.061 0.124 0.088 .725
**
 -.439
*
 0.363 
  p  0.005 0.35 0.777 0.563 0.684 0 0.032 0.081 
NAA+ NAAG r -.740
**
 0.008 0.308 -0.045 -.447
*
 -.612
**
 .749
**
 -.447
*
 
p  0 0.97 0.143 0.833 0.029 0.001 0 0.029 
Glu+Gln r 0.139 -0.084 0.379 -0.098 0.058 .511
*
 .409
*
 0.194 
  p  0.516 0.696 0.068 0.649 0.789 0.011 0.047 0.364 
GPC+ PCho r .702
**
 0.397 -0.245 0.354 .612
**
 0.4 -0.281 .620
**
 
p  0 0.055 0.248 0.09 0.001 0.053 0.184 0.001 
PGC1α r 0.273 -0.143 0.014 0.055 -0.164 -0.027 -0.24 -0.121 
  p  0.208 0.514 0.951 0.802 0.455 0.904 0.27 0.581 
NRF1 r 0.207 -0.104 0.049 0.092 -0.166 -0.082 -0.187 -0.033 
  p  0.344 0.636 0.823 0.676 0.45 0.711 0.393 0.88 
TFAM r -.632
**
 -0.169 0.403 -0.057 -.432
*
 -.539
**
 .684
**
 -0.353 
  p  0.001 0.441 0.056 0.798 0.04 0.008 0 0.099 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
( r )Pearson Correlation  
  ( p)2-Tailed Significance  
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Table A1 (continued) 
  GSH Ins Lac NAA NAAG PE Ser Tau 
pAMPK/AMPK 
r -0.268 .559
**
 -0.054 .414
*
 -0.229 0.398 -0.334 0.067 
p  0.216 0.006 0.807 0.049 0.292 0.06 0.119 0.76 
Cr+PCr r -0.057 .703
**
 -0.188 0.391 -.458
*
 0.169 0.15 0.221 
  p  0.793 0 0.38 0.059 0.025 0.429 0.484 0.3 
Mac r -0.265 0.311 -0.021 .438
*
 -0.045 -0.009 -.636
**
 -.410
*
 
  p  0.211 0.14 0.922 0.032 0.833 0.965 0.001 0.047 
Ala r 0.316 -.448
*
 0.358 -.530
**
 0.207 0.212 0.021 0.2 
  p  0.133 0.028 0.086 0.008 0.333 0.32 0.924 0.348 
Asc r 0.221 .650
**
 -.458
*
 0.404 -0.387 -.721
**
 0.367 -.407
*
 
  p  0.3 0.001 0.024 0.05 0.062 0 0.078 0.048 
Asp r -0.279 .807
**
 -.486
*
 .703
**
 -0.382 0.013 -0.163 -0.193 
  p  0.187 0 0.016 0 0.066 0.953 0.445 0.366 
bHB r -0.053 -0.097 0.342 -0.331 0.217 0.333 0.042 0.253 
  p  0.806 0.653 0.102 0.114 0.308 0.112 0.846 0.233 
GPC r .449
*
 .411
*
 -0.249 0.091 -.407
*
 -.479
*
 .607
**
 0.034 
  p  0.028 0.046 0.241 0.672 0.048 0.018 0.002 0.874 
PCho r 0.339 -.632
**
 0.343 -.742
**
 0.08 0.109 .501
*
 .559
**
 
  p  0.105 0.001 0.101 0 0.709 0.613 0.013 0.005 
Cr r 0.274 0.289 0.15 0.038 -0.138 -0.15 .541
**
 0.2 
  p  0.194 0.171 0.485 0.859 0.52 0.484 0.006 0.35 
PCr r -0.299 .496
*
 -0.33 0.382 -0.366 0.31 -0.311 0.061 
  p  0.156 0.014 0.116 0.066 0.078 0.14 0.139 0.777 
GABA r 0.232 0.053 0.056 -0.083 0.175 0.074 0.376 0.124 
  p  0.275 0.804 0.796 0.701 0.413 0.73 0.07 0.563 
Glc r .470
*
 -0.335 -0.099 -.467
*
 0.133 -0.339 .620
**
 0.088 
  p  0.021 0.109 0.645 0.021 0.536 0.105 0.001 0.684 
Gln r 0.364 -.653
**
 0.34 -.619
**
 0.089 0.33 0.227 .725
**
 
  p  0.08 0.001 0.104 0.001 0.679 0.115 0.287 0 
Glu r -0.202 .842
**
 -.522
**
 .841
**
 -.490
*
 -0.326 -0.135 -.439
*
 
  p  0.343 0 0.009 0 0.015 0.12 0.53 0.032 
GSH r 1 -0.254 0.117 -0.399 -0.18 -0.232 .495
*
 0.363 
  p    0.232 0.587 0.054 0.399 0.276 0.014 0.081 
Ins r -0.254 1 -.473
*
 .789
**
 -0.377 -0.271 -0.071 -.419
*
 
  p  0.232   0.02 0 0.07 0.201 0.743 0.041 
Lac r 0.117 -.473
*
 1 -.528
**
 0.327 0.369 -0.011 0.368 
  p  0.587 0.02   0.008 0.118 0.076 0.96 0.077 
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  GSH Ins Lac NAA NAAG PE Ser Tau 
NAA r -0.399 .789
**
 -.528
**
 1 -0.2 -0.262 -0.391 -.610
**
 
  p  0.054 0 0.008   0.348 0.216 0.059 0.002 
NAAG r -0.18 -0.377 0.327 -0.2 1 0.14 -0.184 -0.248 
  p  0.399 0.07 0.118 0.348   0.514 0.39 0.243 
PE r -0.232 -0.271 0.369 -0.262 0.14 1 -.442
*
 .559
**
 
  p  0.276 0.201 0.076 0.216 0.514   0.03 0.004 
Ser r .495
*
 -0.071 -0.011 -0.391 -0.184 -.442
*
 1 0.276 
  p  0.014 0.743 0.96 0.059 0.39 0.03   0.191 
Tau r 0.363 -.419
*
 0.368 -.610
**
 -0.248 .559
**
 0.276 1 
  p  0.081 0.041 0.077 0.002 0.243 0.004 0.191   
NAA+ NAAG r -.447
*
 .722
**
 -.465
*
 .976
**
 0.018 -0.236 -.440
*
 -.677
**
 
p  0.029 0 0.022 0 0.932 0.267 0.032 0 
Glu+Gln r 0.194 0.156 -0.169 0.193 -.416
*
 0.025 0.111 0.349 
  p  0.364 0.465 0.431 0.366 0.043 0.907 0.605 0.095 
GPC+         
PCho 
r .620
**
 -0.244 0.113 -.573
**
 -0.227 -0.256 .875
**
 .506
*
 
p  0.001 0.25 0.598 0.003 0.286 0.228 0 0.012 
PGC1α r -0.121 -0.34 0.38 -0.254 0.09 0.247 -0.202 0.093 
  p  0.581 0.112 0.074 0.243 0.683 0.257 0.355 0.674 
NRF1 r -0.033 -0.252 .418
*
 -0.238 0.154 0.249 -0.246 0.094 
  p  0.88 0.247 0.047 0.275 0.484 0.252 0.258 0.671 
TFAM r -0.353 .670
**
 -0.253 .690
**
 -0.169 -0.08 -.519
*
 -.539
**
 
  p  0.099 0 0.245 0 0.44 0.715 0.011 0.008 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
( r )Pearson Correlation  
  ( p)2-Tailed Significance  
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Table A1 (continued) 
  NAA+NAAG Glu+Gln GPC+PCho PGC1α NRF1 TFAM 
pAMPK/AMP
K 
r 0.376 0 -0.255 0.061 0.19 .431
*
 
p  0.077 1 0.241 0.782 0.386 0.04 
Cr+PCr r 0.297 0.288 0.094 -0.108 -0.042 0.23 
  p  0.159 0.173 0.661 0.623 0.848 0.29 
Mac r .437
*
 0.033 -.680
**
 -0.186 -0.111 .544
**
 
  p  0.033 0.877 0 0.396 0.615 0.007 
Ala r -.494
*
 -0.075 0.162 0.301 0.372 -0.18 
  p  0.014 0.729 0.45 0.162 0.08 0.41 
Asc r 0.326 -0.037 0.19 -0.145 -0.068 0.297 
  p  0.12 0.864 0.373 0.51 0.759 0.169 
Asp r .632
**
 0.259 -0.282 -0.21 -0.106 .624
**
 
  p  0.001 0.222 0.182 0.336 0.631 0.001 
bHB r -0.289 0 0.179 0.096 0.212 -0.112 
  p  0.17 1 0.401 0.662 0.332 0.611 
GPC r 0.002 0.043 .541
**
 -0.362 -0.299 -0.033 
  p  0.992 0.844 0.006 0.09 0.166 0.881 
PCho r -.740
**
 0.139 .702
**
 0.273 0.207 -.632
**
 
  p  0 0.516 0 0.208 0.344 0.001 
Cr r 0.008 -0.084 0.397 -0.143 -0.104 -0.169 
  p  0.97 0.696 0.055 0.514 0.636 0.441 
PCr r 0.308 0.379 -0.245 0.014 0.049 0.403 
  p  0.143 0.068 0.248 0.951 0.823 0.056 
GABA r -0.045 -0.098 0.354 0.055 0.092 -0.057 
  p  0.833 0.649 0.09 0.802 0.676 0.798 
Glc r -.447
*
 0.058 .612
**
 -0.164 -0.166 -.432
*
 
  p  0.029 0.789 0.001 0.455 0.45 0.04 
Gln r -.612
**
 .511
*
 0.4 -0.027 -0.082 -.539
**
 
  p  0.001 0.011 0.053 0.904 0.711 0.008 
Glu r .749
**
 .409
*
 -0.281 -0.24 -0.187 .684
**
 
  p  0 0.047 0.184 0.27 0.393 0 
GSH r -.447
*
 0.194 .620
**
 -0.121 -0.033 -0.353 
  p  0.029 0.364 0.001 0.581 0.88 0.099 
Ins r .722
**
 0.156 -0.244 -0.34 -0.252 .670
**
 
  p  0 0.465 0.25 0.112 0.247 0 
Lac r -.465
*
 -0.169 0.113 0.38 .418
*
 -0.253 
  p  0.022 0.431 0.598 0.074 0.047 0.245 
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  NAA+NAAG Glu+Gln GPC+PCho PGC1α NRF1 TFAM 
NAA r .976
**
 0.193 -.573
**
 -0.254 -0.238 .690
**
 
  p  0 0.366 0.003 0.243 0.275 0 
NAAG r 0.018 -.416
*
 -0.227 0.09 0.154 -0.169 
  p  0.932 0.043 0.286 0.683 0.484 0.44 
PE r -0.236 0.025 -0.256 0.247 0.249 -0.08 
  p  0.267 0.907 0.228 0.257 0.252 0.715 
Ser r -.440
*
 0.111 .875
**
 -0.202 -0.246 -.519
*
 
  p  0.032 0.605 0 0.355 0.258 0.011 
Tau r -.677
**
 0.349 .506
*
 0.093 0.094 -.539
**
 
  p  0 0.095 0.012 0.674 0.671 0.008 
NAA+ NAAG r 1 0.104 -.636
**
 -0.241 -0.211 .672
**
 
p    0.627 0.001 0.268 0.334 0 
Glu+Gln r 0.104 1 0.151 -0.29 -0.297 0.111 
  p  0.627   0.482 0.179 0.168 0.615 
GPC+ PCho r -.636
**
 0.151 1 -0.038 -0.048 -.603
**
 
p  0.001 0.482   0.864 0.827 0.002 
PGC1α r -0.241 -0.29 -0.038 1 .901
**
 -0.076 
  p  0.268 0.179 0.864   0 0.729 
NRF1 r -0.211 -0.297 -0.048 .901
**
 1 0.035 
  p  0.334 0.168 0.827 0   0.873 
TFAM r .672
**
 0.111 -.603
**
 -0.076 0.035 1 
  p  0 0.615 0.002 0.729 0.873   
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
( r )Pearson Correlation  
  ( p)2-Tailed Significance  
   
 
  
33 
 
Figure A1 – Western Immunoblot of striatum and hippocampus tissue samples.  
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